Jeff is the Managing Partner of Maytal Capital, a healthcare-focused private equity and venture capital firm he founded in 2017, and a Partner at Bridge Builders Collaborative, an early-stage venture firm focused on mental health. He was previously global CEO for Sandoz and Alcon at Novartis Group (NYSE: NVS), where he served on the Executive Committee between 2008 and 2016.
Jeff is Chairman of the Board of Directors at MAPS Public Benefit Corporation, which has an FDA-designated breakthrough therapy for PTSD in late Phase 3 clinical trials, and also serves on the board of directors of Amneal Pharmaceuticals (NYSE: AMRX), a leader in specialty and generic pharmaceuticals with over $2 billion in revenues; 908 Devices (NASDAQ: MASS), a high-growth pioneer in life science diagnostics; and Dorian Therapeutics, a Silicon Valley-based cell therapy biotech spun out of Stanford University. He also serves on several non-profit boards including Education Opens Doors, where he serves as Chairman, the North Texas Food Bank, and YPO of Dallas.
Between 2008 and 2016, Jeff served on the Executive Committee of Switzerland-based Novartis Group, first as the global CEO of Germany-based Sandoz, Novartis’s $10 billion revenue generic pharma and biosimilar subsidiary which doubled in value during his tenure, and then as CEO of Texas-based Alcon, Novartis’s $10 billion revenue eye care division, which was spun out from Novartis as a publicly-listed firm (NYSE: ALC) in 2019. At both Sandoz and Alcon, Jeff was responsible for leading over 25,000 people across more than 160 countries and had leadership responsibility for all functions, regions, and franchises.
Prior to these roles, Jeff headed Emerging Markets for the Middle East, Africa, Southeast Asia, and CIS at Novartis Pharmaceuticals, leading a team of over 3,000 people across 65 markets and serving on its Executive Committee, and as Vice President and Head of Western & Eastern Europe for Novartis Vaccines. Before joining Novartis, Jeff was a Senior Director of Strategic Planning & Business Development at Gap Inc. and an Engagement Manager with McKinsey & Co., both in San Francisco.
Jeff holds an MBA from Harvard Business School and a master’s degree from Johns Hopkins University’s School of Advanced International Studies (SAIS), where he studied international economics and emerging markets political economy and was a John W. Watzek Fellow. He received his B.A. in international relations, magna cum laude and Phi Beta Kappa, from Carleton College. Jeff currently serves as a Board Trustee at Breck School, his high school alma mater in Minneapolis.
Jeff previously served on the Board of Directors of AdvaMed, the medical device industry association, Roam Analytics, a Silicon Valley-based artificial intelligence healthcare software firm sold to Parexel in 2020, and Wishbone Medical, a leader in pediatric orthopedic medical devices. He was twice named to Fortune’s “40 under 40” global leaders list and has lived in seven countries on four continents. He is married and lives with his wife and two daughters in Dallas and Manhattan Beach, California and enjoys live music, running, skiing, surfing, Iyengar yoga, meditation, travel, and foreign affairs.
